Patents by Inventor In Hoo Kim
In Hoo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240294671Abstract: The present invention relates to humanized antibodies having good binding ability to digoxigenin and uses thereof. When an antibody or antigen-binding fragment thereof specifically recognizing digoxigenin according to one aspect of the present invention is used, the concentration of the drug in the body is adjusted as needed through a complex (DOligobody) containing the same, or the concentration of the drug in vivo It is expected that the half-life can be increased.Type: ApplicationFiled: September 28, 2020Publication date: September 5, 2024Applicants: NATIONAL CANCER CENTER, JP BIO A INC., KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATIONInventors: Yun Hee KIM, Kyun HEO, In Hoo KIM, Sun Il CHOI
-
Publication number: 20220259598Abstract: The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues.Type: ApplicationFiled: July 19, 2019Publication date: August 18, 2022Applicants: NATIONAL CANCER CENTER, JP BIO A INC.Inventors: Yun Hee KIM, Kyun HEO, Sun II CHOI, In Hoo KIM
-
Publication number: 20220090081Abstract: The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues as well as high serum stability.Type: ApplicationFiled: August 8, 2019Publication date: March 24, 2022Applicants: JP BIO A INC., NATIONAL CANCER CENTERInventors: Yun Hee KIM, Kyun HEO, Sun II CHOI, In Hoo KIM
-
Patent number: 10435752Abstract: The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.Type: GrantFiled: August 20, 2012Date of Patent: October 8, 2019Assignee: NATIONAL CANCER CENTERInventors: Yeon Su Lee, Sung Ho Goh, In Hoo Kim, Seung Hyun Hong
-
Patent number: 10077430Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.Type: GrantFiled: November 21, 2013Date of Patent: September 18, 2018Assignee: NATIONAL CANCER CENTERInventors: Sang Jin Lee, Yun-Hee Kim, In-Hoo Kim, Seong-Wook Lee, Jin-Sook Jeong, Sang Young Han
-
Patent number: 10042983Abstract: The present invention provides an apparatus for screening cancer, which reads low-mass ion mass spectrum for diagnosing cancer based on biostatistical analysis with respect to low-mass ions extracted from biological materials, and diagnoses cancer using the low-mass ion spectrum. An apparatus for cancer diagnosis, including a low-mass ion detecting unit which detects mass spectra of low-mass ions of biological materials; a cancer diagnosing unit which compares and analyzes patterns of mass spectra and diagnoses cancer; a display unit which displays cancer diagnosis information from the cancer diagnosing unit.Type: GrantFiled: November 30, 2012Date of Patent: August 7, 2018Assignee: NATIONAL CANCER CENTERInventors: Byong Chul Yoo, Kyung Hee Kim, Dae Yong Kim, In Hoo Kim, Ji Won Park, Jae Hwan Oh, Jun Hwa Lee, Eun Sook Lee
-
Patent number: 9640375Abstract: The present invention provides a method for determining low mass ions for diagnosing colorectal cancer by using a MALDI-TOF mass spectrometer to biostatistically analyze low mass ions, which are extracted from a biological sample, and a method for providing information for diagnosing colorectal cancer using same. The present inventions can provide a diagnostic method, which requires low cost and a short time for analysis, can analyze large areas, and which can provide superior and credible discriminations.Type: GrantFiled: August 12, 2011Date of Patent: May 2, 2017Assignee: National Cancer CenterInventors: Byong Chul Yoo, In Hoo Kim, Kyung Hee Kim, Jun Hwa Lee, Kwang Gi Kim, Hee Jin Chang, Dae Yong Kim, Jae Hwan Oh, Byung Chang Kim, Ji Won Park, Sun Young Kim
-
Patent number: 9339557Abstract: Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When the complex is administered to a patient, fluorescence and production of reactive oxygen species from the conjugated photosensitizers are inhibited in normal tissues due to the resonance energy transfer between the photosensitizer and metal nanoparticles, but in tumor tissues, fluorescence and production of reactive oxygen species from the released photosensitizers are activated, thereby effectively destroying the tumor tissues. In addition, the selective fluorescence in the tumor tissues can further improve accuracy of tumor diagnosis using the protease-activatable photosensitizer-metal nanoparticle complex.Type: GrantFiled: October 8, 2009Date of Patent: May 17, 2016Assignee: NATIONAL CANCER CENTERInventors: Yong-Doo Choi, Bo-Seung Jang, In-Hoo Kim, Jin-Young Park
-
Publication number: 20150337270Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.Type: ApplicationFiled: November 21, 2013Publication date: November 26, 2015Inventors: Sang Jin LEE, Yun-Hee KIM, In-Hoo KIM, Seong-Wook LEE, Jin-Sook JEONG, Sang Young HAN
-
Publication number: 20150240313Abstract: The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.Type: ApplicationFiled: August 20, 2012Publication date: August 27, 2015Applicant: NATIONAL CANCER CENTERInventors: Yeon Su Lee, Sung Ho Goh, In Hoo Kim, Seung Hyun Hong
-
Patent number: 9095613Abstract: Provided are a photosensitizer-metal nanoparticle charge complex and a composition for photodynamic therapy or diagnosis containing the same. The complex includes a metal nanoparticle, a photosensitizer charged with a first charge, and a linker bound to the metal nanoparticle and charged with a second charge having an opposite polarity to the first charge. During circulation in blood, the photosensitizer-metal nanoparticle charge complex is maintained in a complex type, and thus duration of a side effect of photosensitivity can be reduced. In a tumor tissue, the complex is specifically accumulated, but in a normal tissue, it is difficult for the complex to penetrate. Thus, the complex can selectively destroy the tumor tissue. Moreover, selective fluorescence in the tumor tissue can provide further improvement in accuracy of diagnosing a tumor using the complex.Type: GrantFiled: October 28, 2009Date of Patent: August 4, 2015Assignee: NATIONAL CANCER CENTERInventors: Yong-Doo Choi, Bo-Seung Jang, Jin-Young Park, Jung-Im Lee, In-Hoo Kim
-
Patent number: 8871438Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of-flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.Type: GrantFiled: August 9, 2012Date of Patent: October 28, 2014Assignee: Korea Research Institute of Standards and ScienceInventors: Tae Geol Lee, Dae Won Moon, Byong Chul Yoo, In Hoo Kim
-
Patent number: 8754033Abstract: Disclosed herein are transglutaminase peptide inhibitors which have inhibitory activity against transglutaminase, and a pharmaceutical composition comprising one of them as an active ingredient. The inhibitors or the composition is useful in the prevention and treatment of various diseases caused by aberrant transglutaminase activation, including inflammatory diseases and cancers. Also, methods for treating various inflammatory diseases and cancers and for preparing mutant peptides capable of inhibiting transglutaminase are also disclosed.Type: GrantFiled: October 11, 2006Date of Patent: June 17, 2014Assignee: National Cancer CenterInventors: Soo youl Kim, In hoo Kim, Sung soo Park
-
Patent number: 8673573Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.Type: GrantFiled: October 7, 2010Date of Patent: March 18, 2014Assignee: National Cancer CenterInventors: Yeon-Su Lee, Sung-Ho Goh, Sung-Hye Hong, In-Hoo Kim, Jin-Sook Jeong
-
Patent number: 8541237Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.Type: GrantFiled: October 26, 2007Date of Patent: September 24, 2013Assignee: National Cancer CenterInventors: In-Hoo Kim, Seong-Wook Lee, Seung-Hee Hong, Jin-Sook Jeong, Yoon-Jong Lee, Yeon-Su Lee, Haeng-Im Jung
-
Publication number: 20130231869Abstract: The present invention provides an apparatus for screening cancer, which reads low-mass ion mass spectrum for diagnosing cancer based on biostatistical analysis with respect to low-mass ions extracted from biological materials, and diagnoses cancer using the low-mass ion spectrum. An apparatus for cancer diagnosis, including a low-mass ion detecting unit which detects mass spectra of low-mass ions of biological materials; a cancer diagnosing unit which compares and analyzes patterns of mass spectra and diagnoses cancer; a display unit which displays cancer diagnosis information from the cancer diagnosing unit.Type: ApplicationFiled: November 30, 2012Publication date: September 5, 2013Applicant: NATIONAL CANCER CENTERInventors: Byong Chul YOO, Kyung Hee KIM, Dae Yong KIM, In Hoo KIM, Ji Won PARK, Jae Hwan OH, Jun Hwa LEE, Eun Sook LEE
-
Publication number: 20130206977Abstract: The present invention provides a method for crystallizing low mass ions for diagnosing colorectal cancer by using a MALDI-TOF mass spectrometer to biostatistically analyze low mass ions, which are extracted from a biological sample, and a method for providing information for diagnosing colorectal cancer using same. The present inventions can provide a diagnostic method, which requires low cost and a short time for analysis, can analyze large areas, and which can provide superior and credible discriminations.Type: ApplicationFiled: August 12, 2011Publication date: August 15, 2013Applicant: NATIONAL CANCER CENTERInventors: Byong Chul Yoo, In Hoo Kim, Kyung Hee Kim, Jun Hwa Lee, Kwang Gi Kim, Hee Jin Chang, Dae Yong Kim, Jae Hwan Oh, Byung Chang Kim, Ji Won PARK, Sun Young Kim
-
Publication number: 20130065266Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of-flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.Type: ApplicationFiled: August 9, 2012Publication date: March 14, 2013Applicant: KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCEInventors: Tae Geol Lee, Dae Won Moon, Byong Chul Yoo, In Hoo Kim
-
Patent number: 8283117Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of- flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.Type: GrantFiled: June 25, 2008Date of Patent: October 9, 2012Assignee: Korea Research Institute of Standards and ScienceInventors: Tae Geol Lee, Dae Won Moon, Byong Chul Yoo, In Hoo Kim
-
Publication number: 20120201837Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.Type: ApplicationFiled: October 7, 2010Publication date: August 9, 2012Applicant: NATIONAL CANCER CENTERInventors: Yeon-Su Lee, Sung-Ho Goh, Sung-Hye Hong, In-Hoo Kim, Jin-Sook Jeong